- Home
- ILLR vs NKTX Comparison
ILLR vs NKTX Comparison
Compare ILLR & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ILLR | NKTX |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 122.5M | 133.5M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | ILLR | NKTX |
|---|---|---|
| Price | $0.76 | $1.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $13.25 |
| AVG Volume (30 Days) | ★ 785.5K | 650.8K |
| Earning Date | 12-12-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $45,244,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.33 | $1.31 |
| 52 Week High | $3.15 | $2.74 |
Technical Indicators
Market Signals| Indicator | ILLR | NKTX |
|---|---|---|
| Relative Strength Index (RSI) | 67.74 | 46.06 |
| Support Level | $0.51 | $1.81 |
| Resistance Level | $0.80 | $1.90 |
| Average True Range (ATR) | 0.08 | 0.07 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 92.27 | 57.50 |
Price Performance
Historical ComparisonAbout ILLR Triller Group Inc.
Triller Group Inc is a us-based company that operates its businesses through Triller Corp which operates as a technology platform and AGBA Group Holding Limited operates as an insurance and wealth distribution platform.
About NKTX Nkarta Inc.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.